The Latest Cardiac and Vascular News
VANCOUVER, Feb. 12, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that Fred Colen, President and Chief Executive Officer of Neovasc, is scheduled to present at the LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14th at 2:30 pm ET at […]
Participating Hospitals in Germany Now Eligible to Negotiate Reimbursement for Reducer Procedure NASDAQ, TSX: NVCN VANCOUVER, Feb. 1, 2018 /PRNewswire/ – Neovasc, Inc. (NVCN) (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve […]
VANCOUVER, Jan. 22, 2018 /PRNewswire/ – Neovasc (“Neovasc” or the “Company“) (Nasdaq, TSX: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the “Board”) has appointed Fred A. Colen as president and chief executive […]
VANCOUVER, Jan. 18, 2018 /PRNewswire/ – Neovasc Inc. today reported its Neovasc Reducer™ (“Reducer”) was featured in a “live case” broadcast to more than 800 participants at the Kardiologie Symposium 2018 held in Berlin, Germany. The successful live case was performed by […]
VANCOUVER, Jan. 8, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ, TSX: NVCN) today provided an update on its clinical program for the Tiara™ (“Tiara”) valve, a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation (“MR”), one of […]
VANCOUVER, Jan. 2, 2018 /PRNewswire/ – Neovasc Inc. (NASDAQ, TSX:NVCN) announced today that it has received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price […]
VANCOUVER, Dec. 6, 2017 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ, TSX: NVCN) today reported its Neovasc Reducer™ (“Reducer”) medical device was featured in a “live case” broadcast at the 2017 Innovations in Cardiovascular Interventions (ICI) conference held in Tel Aviv, […]
VANCOUVER, Nov. 17, 2017 /PRNewswire/ – Neovasc Inc. (NASDAQ, TSX: NVCN) is pleased to announce the closing of its previously announced underwritten offering of 6,609,588 Series A units (the “Series A Units”) and 19,066,780 Series B units (the “Series B Units” and […]
VANCOUVER, Nov. 14, 2017 /PRNewswire/ – Neovasc Inc. (NASDAQ, TSX: NVCN) today announced financial results for the third quarter ended September 30, 2017 (all figures in U.S. dollars unless otherwise indicated). “From a product perspective, our two lead devices continue to perform […]
VANCOUVER, Nov. 10, 2017 /PRNewswire/ – Neovasc Inc.(NASDAQ, TSX: NVCN) today announced that it will release its financial results for the third quarter 2017 on Tuesday, November 14, 2017, after markets close. The Company will subsequently hold a conference call that same […]
